Interleukin-6/interleukin-10 ratio and immune dysregulation after radiofrequency ablation

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 1

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Hepatol. Jan 27, 2026; 18(1): 113429
Published online Jan 27, 2026. doi: 10.4254/wjh.v18.i1.113429

Table 3 Multivariate logistic regression analysis of post-radiofrequency ablation inflammatory markers and clinical parameters

Factor	β value	Odds ratio	95%CI	P value
Intercept value	3.35	28.49	0.08-3.66	0.268
IL-6/IL-10 ratio	0.11	1.11	1.033-1.204	0.006
Albumin (G/L)	-0.21	0.81	0.668-0.961	0.020
Aspartate aminotransferase (IU/L)	0.004	1.004	1.002-1.007	0.002

IL: Interleukin.

Citation: Pang L, Tang D, Zhou WL, Bai X, Zhao HJ, Wang LQ, Cheng W, Wu BL. Interleukin-6/interleukin-10 ratio and immune dysregulation after radiofrequency ablation. World J Hepatol 2026; 18(1): 113429
URL: https://www.wjgnet.com/1948-5182/full/v18/i1/113429.htm
DOI: https://dx.doi.org/10.4254/wjh.v18.i1.113429

Pang L, Tang D, Zhou WL, Bai X, Zhao HJ, Wang LQ, Cheng W, Wu BL. Interleukin-6/interleukin-10 ratio and immune dysregulation after radiofrequency ablation. World J Hepatol 2026; 18(1): 113429 [PMID: 41640970 DOI: 10.4254/wjh.v18.i1.113429]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.